Paclitaxel Package Insert

We appreciate Mr. Hill's comments (Cancer Investigation 14(6):644, 1996) concerning the listing of hypertension in the manufacturer's insert for paclitaxel. We made reference to the (since revised) 1993 insert in our original report because, when it was accepted for publication, that was the current version. At the time our manuscript was prepared, hypertension had not yet been included in the package insert nor were we able to locate any published reports of this reaction to paclitaxel. This lack of information was one of the impetuses that prompted our report. It is unfortunate that the delay between submission of our report (January 1995) and its publication (July 1996) rendered some of the information obsolete.